Cancer vaccine plus immunotherapy shows promise in advanced lung and Head/Neck tumors

NCT ID NCT02955290

First seen Nov 10, 2025 · Last updated May 13, 2026 · Updated 21 times

Summary

This study tests a combination of the CIMAvax vaccine (which targets a protein that helps tumors grow) and nivolumab (an immunotherapy that boosts the immune system) in people with advanced non-small cell lung cancer or squamous head and neck cancer. The goal is to find the best dose and see if the combination can slow tumor growth and improve survival. About 51 adults with these cancers that have spread or cannot be removed are participating.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Good Samaritan Hospital

    West Islip, New York, 11795, United States

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana, 46202, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • St. Francis Hospital

    Roslyn, New York, 11576, United States

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

Conditions

Explore the condition pages connected to this study.